In addition, we had previously confirmed key oncogenic or pro‐metastatic roles for TBX2 and TBX3 in 501mel cells [26, 27] and it was anticipated that any drug that impacts TBX2/TBX3 levels and nuclear localisation in these cells would do the same in other TBX2/TBX3‐driven cancers such as rhabdomyosarcoma (RMS). This evidence concerns the gene TBX3 and rhabdomyosarcoma.